The United States Food and Drug Administration (FDA) has approved several related drugs that target CTLA-4, PD-1, and its ligand PD-L1, for the treatment of advanced melanoma, non-small cell lung cancer, Hodgkin’s lymphoma, and head and neck cancer (23–27). Here, CTLA4 is linked to melanoma.